Бипрол

Quick links to important sections

Бипрол

Selected form

Treatment option: Hypertension, Heart Failure

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Бипрол

What is Бипрол? Defining the Drug's Identity

Property Description
Active ingredient Bisoprolol fumarate
Form Film-coated tablets (oral)
Pharmacological class Beta-blocker (beta-adrenoceptor antagonist)
Common use Management of cardiovascular conditions (General)
Origin Synthetic compound

Бипрол is a prescription-only medicine whose identity is fundamentally derived from its active ingredient, Bisoprolol fumarate. The drug is formulated for oral administration, typically supplied as film-coated tablets. Бипрол is recognized as a specific trade name for this formulation, ensuring a defined, standardized presentation of the compound.

The core substance, Bisoprolol fumarate, is classified as a high-purity synthetic compound, which ensures molecular consistency and reliable pharmacological activity. As a single-ingredient product, Бипрол contains only this active therapeutic substance alongside standard pharmaceutical excipients necessary for forming the solid dosage tablets. Bisoprolol is an agent used for long-term cardiovascular therapy.

The Pharmacological Type: A Cardioselective Beta-Blocker

Бипрол belongs to the major pharmacological class of beta-blockers, or beta-adrenoceptor antagonists. More specifically, it is designated as a highly selective beta1-adrenoceptor blocker, functioning as a sympatholytic agent.

This classification defines the mechanism of action, which primarily targets and inhibits the effects of the sympathetic nervous system on the heart. The cardioselective nature of Bisoprolol means that its inhibitory activity is concentrated on the beta1-receptors, which are predominately located in the heart muscle. This focused action is a key feature distinguishing it from older, non-selective beta-blockers that affect a broader range of receptors throughout the body.

General Purpose: Reducing Strain on the Heart

The general purpose of Бипрол is to decrease the overall workload and oxygen demand of the heart muscle, thereby relieving physical cardiovascular strain. This high-level therapeutic goal is a key approach in chronic cardiovascular management.

The active substance exerts a physiological action that includes reducing the heart rate and moderating the force of heart muscle contractions. By slowing the heart's rhythm and decreasing its pumping effort, Бипрол supports the heart's function and aids in the management of cardiovascular dynamics.

Regulatory References

  1. National Institutes of Health

What side effects are possible with Бипрол?

Possible side effects and safety information

The safety profile of Бипрол (Bisoprolol fumarate) is characterized by official classifications of adverse reactions based on frequency and the body system affected, as documented by regulatory authorities.

Adverse Reaction Classifications

Side effects are categorized by how often they appear in clinical use. Very Common adverse events (affecting more than 1 in 10 patients) include bradycardia (slow heart rate), particularly in patients with chronic heart failure. Common reactions (1 to 10 in 100 patients) often involve the Nervous System (dizziness, headache) and General Disorders (fatigue, asthenia). Gastrointestinal complaints, hypotension, and the feeling of coldness or numbness in the extremities are also classified as Common.

Uncommon effects include sleep disturbances, depression, and disturbances of the heart’s electrical conduction (AV-conduction disturbances). Rare events (1 to 10 in 10,000 patients) involve reactions such as hepatitis, hypersensitivity reactions (rash, itching), and syncope. Serious adverse reactions, such as Cardiogenic Shock or a severe degree of Atrioventricular block, are listed as situations where the medicine should not be used (contraindications).

Safety Considerations and Exposure Patterns

Official labeling defines specific safety patterns. Certain common effects, like fatigue and dizziness, are documented as especially occurring at the beginning of the therapy and typically resolve within the first one to two weeks. The safety profile also includes Population-Specific Safety Notes; for example, safety and effectiveness have not been established in the pediatric population. Caution is required in patients with severe hepatic or renal impairment due to altered drug elimination, and in patients with diabetes, as the medicine may mask symptoms of hypoglycemia.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Bisoprolol fumarate defines overdose based on profound physiological disturbances resulting from excess beta-blockade. Documented overdose presentations include critical cardiovascular signs such as severe bradycardia (abnormally slow heart rate) and marked hypotension (low blood pressure).

Further documented manifestations involve atrioventricular conduction disturbances, bronchospasm, and systemic effects like hypoglycemia. Overdose is classified as potentially severe and life-threatening, with risks escalating to cardiogenic shock, coma, and convulsions.

Required Emergency Actions

Due to the potential for severe outcomes, regulatory statements mandate that individuals must seek immediate medical attention for any suspected overdose. Emergency services or a Poison Control Center must be contacted at once. Hospital monitoring is required for management.

While no specific antidote is known, official management requires immediate symptomatic and supportive treatment, including the documented use of agents such as Glucagon or Atropine as necessary for stabilization. Specific regulatory notes highlight that hypoglycemia is a common and critical concern in pediatric overdose.

Therapeutic Uses of Бипрол

What Бипрол Treats: Main Uses and Benefits

The primary role of Бипрол is to provide long-term management and therapeutic support for several chronic cardiovascular conditions. Its main uses include treating high blood pressure, managing chronic stable angina, and stabilizing heart failure. It is applied across domains where additional symptomatic support is needed, assisting with maintaining functional stability and supporting the patient during difficult episodes.


This medication is commonly used as a core component in the sustained management of chronically high blood pressure levels and is commonly used as a supportive component of therapy for patients with stabilized chronic heart failure. It is also used to help with the prevention and easing of symptoms related to recurrent episodes of chest pain and discomfort (angina), as well as to moderate and control an excessively fast or irregular heart rate associated with certain cardiac arrhythmias.

“The medication is relevant when symptoms related to systemic imbalance, like undue fatigue and shortness of breath, interfere with daily functioning.”

By helping to address symptom clusters that may become intense or disruptive, Бипрол provides supportive relief when symptoms create noticeable physiological strain. Its use helps maintain a sense of stability when symptoms are more noticeable, contributing to easing the overall symptom load and helping patients cope more steadily.


Quick Fact: Focus on Symptoms Related to Systemic Strain

Eligibility and Restrictions for Use

The eligibility for Бипрол (Bisoprolol) is strictly defined by regulatory documents, distinguishing between populations permitted, restricted, or prohibited from use. Use is established for adults and the elderly.

Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated in patients with unstable, severe cardiovascular conditions, including acute heart failure or decompensation, cardiogenic shock, and specific rhythm disorders like second or third-degree AV block (without a pacemaker) and symptomatic bradycardia. Prohibition also applies to individuals with severe bronchial asthma, late-stage peripheral arterial occlusive disease, and untreated phaeochromocytoma. Contraindication also applies to patients with known hypersensitivity to the drug substance.

Age and Condition Restrictions

  • Pediatric Use: Use in children and adolescents is not recommended as the safety and efficacy profiles have not been established.
  • Organ Impairment: Eligibility is limited for patients with severe renal or hepatic impairment, often requiring a reduced maximum daily dose due to limited therapeutic experience and caution.
  • Pregnancy/Lactation: Use during pregnancy is restricted and not recommended unless clearly essential. Use while breastfeeding is also generally not recommended based on regulatory guidance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Bisoprolol (Бипрол) details several categories of clinically relevant drug interactions, primarily concerning effects on heart rhythm and blood pressure. The most critical restriction is that Bisoprolol should not be combined with other beta-blocking agents due to the potential for additive pharmacologic effects.

Caution is advised when co-administering certain calcium channel blockers (specifically verapamil and diltiazem) and Class I antiarrhythmic agents (e.g., disopyramide) because these combinations can increase the risk of bradycardia and heart block. Similarly, concurrent use of digitalis glycosides and catecholamine-depleting drugs (e.g., reserpine) requires close monitoring for excessive slowing of the heart rate or excessive reduction of sympathetic activity.

For patients taking clonidine, a specific procedural constraint is required: Bisoprolol should be discontinued several days before the withdrawal of clonidine to manage withdrawal effects. Interactions with metabolic pathways include rifampin, which can increase Bisoprolol's clearance, though initial dose adjustment is typically unnecessary. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may diminish the antihypertensive effect. Additionally, the drug may mask the symptom of tachycardia in patients using insulin or oral hypoglycemic agents, necessitating awareness for diabetic patients. Regulatory data indicates no clinically relevant interactions with warfarin, cimetidine, or thiazide diuretics.

Mechanism of Action

How Бипрол Works

Бипрол (Bisoprolol) is an agent that exhibits selectivity for the beta1-adrenergic receptor, modulating cardiovascular and renal activity by interfering with specific signaling pathways. Its primary action centers on dampening the effects of the sympathetic nervous system on the heart and influencing pathways associated with systemic pressure control.


beta1-Receptor Blockade: Modulating Cardiac Signaling

The primary mechanistic action involves the competitive blockade of beta1-adrenergic receptors found predominantly in the myocardium (heart muscle). By preventing the binding of catecholamine signaling molecules like norepinephrine, the drug interferes with the G-protein signaling cascade. This mechanism reduces the intrinsic rate of sinus node discharge and the speed of atrioventricular conduction, leading to a reduction in the frequency of action potentials and contractile force within the heart muscle.


Humoral Regulation: Influencing the Renin Pathway

This mechanistic influence extends to systemic regulatory cascades, particularly the Renin-Angiotensin System (RAS). The blockade of beta1-receptors on renal juxtaglomerular cells suppresses the synthesis and release of renin, a key enzyme that initiates the RAS cascade. Modifying this early molecular step alters the resulting downstream effects of elevated mediator activity, influencing the mechanisms that govern vascular tone and systemic pressure.

Dosage and Administration Information

The administration of Бипрол (Bisoprolol fumarate) follows defined protocols regarding its route, frequency, and dose adjustment. The medication is delivered via the oral route, formulated as film-coated tablets that must be swallowed whole with liquid and should not be crushed or chewed. The required dosing frequency for all approved uses is once daily, often taken in the morning, and intake is independent of meals.

Usage is characterized by a commitment to individualized dosing that begins at a low dose and is gradually increased. For conditions such as hypertension and stable angina pectoris, the usual starting dose ranges from 2.5 mg to 5 mg, with a maintenance dose typically at 10 mg once daily, not to exceed the maximum recommended dose of 20 mg. The protocol for chronic heart failure is unique, mandating an initial dose of 1.25 mg once daily followed by a slow titration phase over several weeks until the target dose of 10 mg is reached. This process is structured to require close monitoring during the adjustment period.

In specific populations, the daily dose generally should not exceed 10 mg for patients with severe renal or hepatic impairment. Furthermore, use in pediatric patients is typically not recommended due to a lack of sufficient clinical data. This medicine is intended for long-term continuous management; treatment is not stopped abruptly, but rather the dose is tapered gradually over a one-to-two-week period.

Recent Clinical Evidence

Research evidence / Overview of Studies for Бипрол

The research base for Bisoprolol fumarate (Бипрол) is extensive, primarily built on large-scale clinical investigations like Randomized Controlled Trials (RCTs) and comprehensive Meta-analyses. These studies explore the use of the medication in chronic cardiovascular conditions, tracking long-term outcomes, functional capacity, and symptom patterns.


Evidence for Use in Chronic Heart Failure

Core evidence for chronic heart failure comes from multiple large-scale, placebo-controlled RCTs that included thousands of adult patients with stable heart failure characterized by reduced ejection fraction (HFrEF). Researchers examined long-term outcomes, which centered on critical measures like all-cause mortality, cardiovascular death, and the rate of hospitalization for heart failure-related events. Studies also monitored metrics of the heart's function, such as Left Ventricular Ejection Fraction (LVEF), and patient-reported measures of functional status.

Studies monitored groups receiving the medication for differences in the incidence of these major clinical events over periods often extending beyond one year, and findings describe the patterns observed in these data. Trial reports also reported that the initiation of this medication requires a carefully managed and gradual adjustment process under supervision.

What remains uncertain: Limited specific data are available from dedicated large trials focusing on heart failure patients who have certain co-existing conditions, particularly advanced kidney failure. Research exploring the medication for other forms of heart failure, such as heart failure with preserved ejection fraction (HFpEF), is still developing, and this use is not part of the approved evidence.


Evidence for Use in High Blood Pressure and Angina

For the management of high blood pressure, research has been conducted using both Randomized Controlled Trials and long-term Population-based Cohort Studies. Research examined outcomes related to overall cardiovascular health, specifically monitoring the reduction in systolic and diastolic blood pressure as a short-term metric. Long-term studies examined the incidence of major events like stroke and myocardial infarction (MI). Studies observed that lower blood pressure readings were recorded in the study populations during the period of use.

For chronic stable angina, evidence comes from controlled trials and observational settings. Research primarily examined outcomes related to physical discomfort and symptom patterns, focusing on how often patients experienced angina episodes and their use of fast-acting relief medications. Studies monitored patient-reported outcomes describing perceived discomfort and assessed exercise capacity by observing the time it took for symptoms to manifest during standardized physical activity.


Research on Heart Rate and Rhythm Control

The medication was studied for managing an overly rapid heart rate, particularly in conditions like Atrial Fibrillation. Research examined its role in achieving and maintaining a controlled heart rate. Studies monitored the degree of heart rate reduction achieved in observed populations and tracked the recurrence of arrhythmia episodes.

What remains uncertain: Clinical use of the medication has been evaluated, but the evidence supporting its use for chronic rate control relies less on large, dedicated, long-term outcome RCTs than the heart failure indication does. Comparative evidence against other rate-controlling or rhythm-controlling drugs is variable across different forms of arrhythmia, and data for certain complex or rare ventricular arrhythmias remain insufficient.


Evidence in Specific Patient Groups

The research has explored the use of Bisoprolol in older adults and in patients with co-existing conditions, including diabetes and specific stages of kidney disease, mainly within the context of heart failure trials. Subgroup analyses indicate that the patterns observed in the overall heart failure population were also described in older patient subgroups.

What remains uncertain: Specific, dedicated, large-scale studies focusing exclusively on the long-term outcomes in pediatric populations have not been widely reported in the authorized literature. Similarly, research for populations with certain severe or rapidly progressive co-morbidities often lacks the extended follow-up required to fully characterize the long-term effects, as the results apply only to the populations studied in the primary trials.

Frequently Asked Questions (FAQ)

Common questions about Бипрол (FAQ)

Q: What are the most commonly reported side effects of Бипрол?

Official safety documents classify certain effects as common, meaning they are observed in many patients in clinical studies. These include a slow heart rate (bradycardia), dizziness, headache, fatigue, a sensation of coldness or numbness in the extremities, and general stomach complaints such as nausea or constipation.

Q: How quickly does a person typically start to notice the effect of Бипрол?

Pharmacological effects, such as a reduction in heart rate, can begin within a few hours after taking a dose. However, for conditions like high blood pressure, the full therapeutic benefit may take several weeks of consistent use to become fully established.

Q: Can Бипрол be taken with blood pressure medications?

This medicine is often used as part of a combination therapy with other heart failure medications. However, official guidance states that its use alongside other beta-blockers is generally not recommended (contraindicated). Caution is also advised when combining it with specific types of calcium channel blockers, such as those containing verapamil or diltiazem.

Q: Are there any known interactions between Бипрол and common over-the-counter pain relievers?

Regulatory information notes that certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may diminish the blood pressure-lowering effect of this medicine. No other major interactions with common over-the-counter pain relievers are consistently reported across authoritative regulatory documents.

Q: Does taking Бипрол require routine monitoring or blood tests?

Official guidance indicates that a healthcare professional should check patient progress at regular intervals. This monitoring is designed to help determine if the medicine is working as expected and to detect unwanted effects. Close follow-up is especially recommended during the initial period of dose adjustment.

Q: Are headaches a known side effect of Бипрол?

Yes, official documents list headaches as a common adverse reaction that people may experience while using this medicine.

Q: What should be done if a patient feels dizzy or lightheaded while using Бипрол?

Dizziness or lightheadedness are common effects, especially when first starting therapy. Regulatory documents indicate that patients should seek the guidance of a healthcare professional immediately if these symptoms are accompanied by signs of heart problems, such as unusual weight gain, swelling, or shortness of breath.

Q: Is it common to feel tired when first starting Бипрол?

Fatigue is a common side effect reported in clinical studies. Official safety information notes that feelings of tiredness and dizziness are especially likely to occur at the start of therapy. These common initial effects are often noted to lessen or resolve within the first one to two weeks.

Q: Can elderly patients use Бипрол?

Regulatory documents confirm that studies included older patients, and their response was generally similar to that of younger adults. Official documents note that because this medicine is eliminated from the body slower in older populations, monitoring may be required.

Q: What happens if a dose of Бипрол is missed?

If a dose is missed, label information describes the protocol of taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is described as being skipped to continue the regular schedule. A double dose must never be taken to compensate for a missed one.

Q: What are the known severe side effects that require immediate attention?

Regulatory information lists certain serious symptoms, such as chest pain or sudden shortness of breath, which indicate the need for immediate consultation with a healthcare professional. Other signs include extreme fatigue, unusual or rapid weight gain, or swelling of the hands, feet, ankles, or lower legs.

Q: Are there specific foods or drinks that should be avoided while taking Бипрол?

Official sources generally advise continuing a normal diet unless otherwise guided by a healthcare professional.

Q: Does Бипрол cause weight gain?

Weight changes are reported in clinical studies as a common metabolic disorder. Unusual or rapid weight gain is a specific symptom that regulatory documents indicate should be monitored immediately by a healthcare professional.

Q: How long does Бипрол stay in the system after the last intake?

The half-life, which is the time it takes for the amount of medicine in the body to be reduced by half, is approximately 9 to 12 hours. This pharmacokinetic characteristic is consistent with the drug’s use as a once-daily medicine.

Q: Is chest pain a reported side effect of Бипрол?

Chest pain has been reported as a less common side effect. Regulatory documents also include a warning that abrupt withdrawal of this medicine without gradual tapering has been associated with chest pain (angina).

Q: Is it typical for side effects of Бипрол to lessen over time?

Yes, according to official safety information, common effects like fatigue and dizziness are especially documented at the start of therapy. These common initial effects are often noted to lessen or resolve within the first one to two weeks as the body adjusts.

Q: Can other medicines influence the effectiveness of Бипрол?

Yes, certain drugs can influence how well this medication works. Regulatory information specifically notes that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may diminish the blood pressure-lowering effect achieved by this medicine.

Q: Why is it important to describe all current medications to a healthcare provider before starting Бипрол?

It is important to disclose all prescription, nonprescription medicines, vitamins, supplements, and herbal products. This disclosure allows a healthcare professional to fully evaluate the possibility of potential interactions, which can affect the risk of adverse effects or the medicine's effectiveness.

Q: Is Бипрол used for the prevention of certain cardiac events?

The use of this medicine is part of a long-term strategy for managing chronic cardiovascular conditions. Clinical investigations track patient outcomes, focusing on critical measures like all-cause mortality, cardiovascular death, and the rate of hospitalization for heart failure.

Q: Do official documents mention any connection between Бипрол and sleep disturbances?

Yes, sleep disorders and depression are listed in official documents as uncommon adverse effects. More specific issues, such as nightmares and hallucinations, are classified as rare effects.

Q: Can people with liver impairment use Бипрол?

Use is limited and requires caution in patients with severe hepatic (liver) impairment. Official guidance notes that the dose may require adjustment due to the slower elimination of the medicine in these cases.

Q: What is the duration of action for a single dose of Бипрол?

Pharmacodynamic studies show that the effects related to heart rate and blood pressure can persist for up to 24 hours at doses of 5 mg or greater. This extended action is consistent with the regulatory requirement for once-daily dosing.

Q: How does the approved use of Бипрол relate to heart failure?

This medicine is approved for the management of chronic stable heart failure. Official protocols for this use describe a uniquely slow and carefully monitored dose-titration phase, and research evidence focuses on long-term outcomes for patients with this condition.

Q: Are there specific restrictions on physical activity while taking Бипрол?

There are no specific blanket restrictions on physical activity in the official labeling. However, this medicine works by slowing the heart rate, which may affect the heart's natural response to exercise.

Q: What are the most significant safety warnings associated with Бипрол?

Significant warnings documented in official sources include the risk of serious heart problems if the medicine is stopped abruptly without gradual tapering. It is also strictly not recommended (contraindicated) for use in patients with certain severe pre-existing cardiac conditions, such as cardiogenic shock.

Q: Does Бипрол affect a person's ability to drive or operate machinery?

Official documents warn that due to the potential for common side effects like dizziness and fatigue, activities requiring full alertness, such as driving or operating machinery, should be avoided if these effects are experienced.

Q: Does the time of day matter when taking Бипрол?

The medicine is typically taken once daily. Official information often suggests taking it in the morning, but the regulatory documents note that the first dose may be taken later in the day.

How should Бипрол be stored and disposed of?

The storage and disposal of Бипрол (bisoprolol fumarate) tablets are strictly governed by regulatory requirements to ensure product quality and public safety.

Storage Conditions

Бипрол must be stored at controlled room temperature, generally between 20 C and 25 C (68 F and 77 F). The product must not be frozen and must be protected from excessive heat and moisture. To maintain stability, the tablets must remain in their original container and be kept tightly closed.

Stability and Safety

Specific formulations may have a limited shelf-life after opening (e.g., 6 months). For safety, this medicine must always be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired tablets must not be disposed of in household trash or via wastewater. Disposal should be carried out according to local and national regulations, often requiring return to a pharmacy or participation in an authorized drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Бипрол found in:

A-Z Index: